ClinicalTrials.gg
Sign In

Hemorrhagic Disorders clinical trials

The registry lists 63 studies for Hemorrhagic Disorders across more than 10 countries. 12 are recruiting or about to start. 8 of them are mainly about Hemorrhagic Disorders (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-06. Counting its 17 narrower conditions too, such as Multiple Myeloma: 6,521 studies, 1,337 open.

Get an email when these change. Save the Hemorrhagic Disorders studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
34
Recruiting
10
Terminated
5
Active, not recruiting
4
Status unknown
4
Withdrawn
4

Phase

Phase 3
17
Phase 1
17
Phase 2
14
Phase 4
3

Where

United States
29
United Kingdom
18
France
17
Australia
14
Spain
13
Germany
11

Who runs them

BioMarin Pharmaceutical (8) · Swedish Orphan Biovitrum (6) · Spark Therapeutics, Inc. (3) · Seagen Inc. (2) · Genzyme, a Sanofi Company (2) · Kedrion S.p.A. (2) · Takeda (2) · Baxalta now part of Shire (2)

What is being tested here

Drugs under test in Hemorrhagic Disorders studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Mezagitamab222
Immunoglobulins, Intravenous111
Immunoglobulin G111
Valoctocogene Roxaparvovec047
Pacritinib022
Fitusiran022
Dacetuzumab002
ARQ531001
Elranatamab001
At-7519m001

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 6 · JAK inhibitors 4

Coming up

5phase 3 studies under way
4studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 4, phase 3 first

Who these studies take

Of the 10 Hemorrhagic Disorders studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger. 1 (10%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (10%) take healthy volunteers.

Recruiting studies that take each age, of 10
AgeWomenMen
100 (0%)0 (0%)
189 (90%)9 (90%)
3010 (100%)10 (100%)
4010 (100%)10 (100%)
5010 (100%)10 (100%)
6510 (100%)10 (100%)
759 (90%)9 (90%)
856 (60%)6 (60%)

Across all 63 studies, recruiting or not: 16% stop at 75 or younger and 6% at 65; 24% take children; 2% are for women only and 25% for men only; 11% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Hemorrhagic Disorders studies take

Of 14 observational studies under Hemorrhagic Disorders, half reached primary completion within 42 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Observational42 mo27–54 · 14 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 63. Browse all 63 → or search them.